• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » EU launches full-scale probe into $54B Essilor-Luxotica merger

EU launches full-scale probe into $54B Essilor-Luxotica merger

September 29, 2017 By Sarah Faulkner

Luxottica, EssilorThe European Commission plans to investigate whether the €46 billion merger of Luxottica (NYSE:LUX) and Essilor (EPA:EI) could drive competitors away from the market or hike prices, according to Reuters.

The companies hold high-ranking positions in the ophthalmic lens and eyewear industries. Earlier this month, Luxottica and Essilor decided not to offer concessions in a preliminary review by antitrust authorities.

The agency said it plans to decide whether to clear the deal or not by February next year, but the two companies said they hope to close the merger at the end of this year.

“Both companies … will closely cooperate with the European Commission to fully demonstrate the rationale of the proposed combination,” they said in a joint statement, Reuters reported.

One concern that antitrust authorities have is that the merged company might encourage opticians to buy eyewear and lenses in packages. The Commission wants to ensure that Luxottica’s rivals have access to the lens market and Essilor’s rivals have access to the frames market.

“The final outcome will hinge to a large extent on concessions the two companies make to offset any foreclosure risks,” Luciano Di Via, head of antitrust affairs for Italy, told the newswire.

“Usually in situations such as this, behavioural remedies are requested, the commission may demand commitments from the two companies in terms of commercial practices, a request to sell certain assets is more unlikely.”

“Half of Europeans wear glasses and almost all of us will need vision correction one day,” European Competition Commissioner Margrethe Vestager told Reuters.

“We need to carefully assess whether the proposed merger would lead to higher prices or reduced choices for opticians and ultimately consumers.”

The merger is still waiting for clearance in the U.S., but it has been approved in India, Japan and New Zealand.

($1 = 0.8490 euros)

Material from Reuters was used in this report.

Filed Under: Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: Essilor, Luxottica

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy